Steven I. Gutman, M.D., M.B.A.

Steven I. Gutman, M.D., M.B.A.

Dr. Gutman is a board-certified pathologist with a BS degree from The Ohio State University, an MD degree from Cornell University Medical College, and an MBA degree from the State University of New York at Buffalo. He completed residency training in anatomical pathology at Cornell and clinical pathology at the Mayo Clinic. After 10 years of experience as a clinical pathologist and chief of laboratory service at the Buffalo Veterans Administration Medical Center, he joined the Division of Clinical Laboratory Devices at FDA as a medical officer in 1992. Dr.

Gary B. Gordon, M.D., PhD

Gary B. Gordon, M.D., PhD

In Dr. Gordon current role, he oversees development of AbbVie’s oncology projects. He joined AbbVie in April 2003 and assumed his current role in July 2004. Prior to joining AbbVie, Dr. Gordon was chief scientific officer and vice president of clinical affairs at Ovation Pharmaceuticals from 2001 to 2003. In this role, he helped obtain funding and introduce five therapies to the market.

Anthony Weeks, MFA, MSW

Anthony Weeks, MFA, MSW

Anthony Weeks is a documentary filmmaker, illustrator, and writer based in San Francisco, CA. He has more than fourteen years of experience working with senior-level product and strategy development teams to think visually and turn data into stories.   As both an information designer and illustrator, Anthony collaborates with project teams to create visually-rich graphic chronicles and murals of their strategic conversations, often in real time, as a catalyst for facilitating dialogue, clarifying vision, and animating the process of ideation.

David Wholley, Ph.D.

David Wholley, Ph.D.

David Wholley manages The Biomarkers Consortium for the Foundation for the National Institute of Health.  He has also served as Director of the Genetic Association Information Network (GAIN), a public-private partnership dedicated to helping discover the genetic basis of common disease, and led the development of a major public-private partnership in drug safety with the biopharmaceutical industry and FDA. Prior to joining the Foundation in 2006 Mr.

Joe Vockley, Ph.D.

Joe Vockley, Ph.D.

Joe Vockley received a BS in microbiology from The Pennsylvania State University, a Ph.D. in Molecular Genetics from The University of Delaware and completed a 3 year clinical genetics residency and post-doctoral fellowship at The University of California at Los Angeles (UCLA)/Cedars Sinai Medical Center.

He has 30+ years of experience in genetic, genomic and bioinformatics research in academia, the biotechnology sector, pharmaceutical companies and the US Government.

George Vasmatzis, Ph.D.

George Vasmatzis, Ph.D.

Dr. George Vasmatzis is the director of the Biomarker Discovery Program, within the Center for Individualized Medicine, and his research program consists of bioinformatics specialists, molecular biologists, epidemiologists, and pathologists. He is a Consultant in the Department of Molecular Medicine and a member of the Mayo Clinic Cancer Center. He is also an Assistant Professor in the Department of Laboratory Medicine at the Mayo Medical School.  He has a Ph.D.

Laura van ‘t Veer, Ph.D.

Laura van ‘t Veer, Ph.D.

Dr. van ‘t Veer is a world renowned Molecular Biologist, former Head of Diagnostic Oncology at the Netherlands Cancer Institute, and inventor of MammaPrintÒ. She is the Leader of the Breast Oncology Program in the Helen Diller Family Comprehensive Cancer Center and a convenor of UCSF’s Precision Medicine Platform. Dr. van ‘t Veer’s research focuses on Personalized Medicine, to advance that patient management is based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient.

Jeffrey M. Trent, Ph.D.

Jeffrey M. Trent, Ph.D.

Jeffrey M. Trent, Ph.D., F.A.C.M.G., is founding President and Research Director of the Translational Genomics Research Institute (TGen). He specializes in developing and integrating novel “omic” technologies, supporting studies of molecular changes related to the predisposition to, and progression of, human cancers and other complex diseases. He has held numerous faculty appointments including at the University of Arizona, the University of Michigan, Johns Hopkins University and Arizona State University.

Elizabeth Sheppard, MBA

Elizabeth Sheppard, MBA

Ms. Sheppard has worked in both private and academic management of Anatomic Pathology laboratories for the past 30 years. Her educational background includes degrees in Histotechnology, Biology and a Masters in Business Administration.

Her faculty experience consists of Clinical Experience Advisor, and Instructor, State University of New York at Cobleskill, Faculty, Wake Forest University School of Medicine, Fundamental of Pathology and Adjunct Faculty at Pima County Community College Histology Program.

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS